Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Phase IV, Randomized, Controlled, Observer Blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Trivalent Subunit Inactivated Influenza Vaccine in Healthy Subjects Aged 50 Years and Above

NCT01867021 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT01867021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01867021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Phase IV, Randomized, Controlled, Observer Blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Trivalent Subunit Inactivated Influenza Vaccine in Healthy Subjects Aged 50 Years and Above
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2013
Completion date
December 31, 2013
Enrollment
2,902 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

influenza